Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Study sponsor: Kyntra Bio
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-07Actual
Enrollment · participants21Actual
Source updated2024-08-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.